Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase 1 clinical trial for AVA6000, a novel peptide drug conjugate. The trial, leveraging Avacta’s proprietary pre|CISION technology, has successfully completed the first cohort and initiated dosing for three patients in the second cohort. This advancement is part […]
Nordson EFD, a subsidiary of Nordson Corporation (NASDAQ: NDSN) and a frontrunner in the manufacture of precision fluid dispensing systems, has unveiled its latest advancements in automation technology—the GVPlus and PROX families of automated fluid dispensing solutions. These innovations are set to redefine standards in precision and flexibility for various manufacturing sectors, heralding a new […]
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in its drug development journey. The company has successfully dosed the third patient in the first cohort of the two-weekly Phase 1a dose escalation study of AVA6000. This peptide drug conjugate, […]